Lipid Metabolism Practice Questions

Q: Arachidonic acid oxidation involves how many cycles of beta oxidation?

9. ***Correct Answer: 9*** - **Arachidonic acid** is a 20-carbon fatty acid (C20:4). For a fatty acid with *n* carbons, the number of beta-oxidation cycles required is **(n/2) - 1**. - Therefore, for **arachidonic acid** (n=20), the number of beta-oxidation cycles is (20/2) - 1, which equals 10 - 1 = **9 cycles**. - Each cycle removes 2 carbons as acetyl-CoA, shortening the fatty acid chain progressively. *Incorrect Option: 10* - This number represents the total number of **acetyl-CoA** molecules generated from a 20-carbon fatty acid, not the number of beta-oxidation cycles. - Each beta-oxidation cycle produces one **acetyl-CoA** and reduces the fatty acid chain by two carbons; the last cycle yields two **acetyl-CoA** molecules directly. *Incorrect Option: 20* - This value corresponds to the total number of carbons in **arachidonic acid**, not the number of beta-oxidation cycles. - The number of beta-oxidation cycles is significantly less than the total carbon count. *Incorrect Option: 8* - This number would be correct for an 18-carbon fatty acid like **stearic acid** (18/2 - 1 = 8), not for **arachidonic acid**. - The calculation explicitly depends on the exact number of carbon atoms in the fatty acid chain.

Q: All are true about beta oxidation of fatty acids except which of the following?

Carnitine Acyl transferase I is stimulated by malonyl CoA. ***Carnitine Acyl transferase I is stimulated by malonyl CoA*** - Malonyl CoA is a key intermediate in **fatty acid synthesis** and acts as an **inhibitor** of carnitine acyltransferase I (CAT1), not a stimulator. - This inhibition ensures that when fatty acid synthesis is active, fatty acid oxidation is suppressed, preventing a futile cycle. *Carnitine acyl transferase I is the rate limiting enzyme of fatty acid oxidation* - **Carnitine palmitoyltransferase 1 (CPT1)**, also known as carnitine acyltransferase I, is indeed the **rate-limiting step** for long-chain fatty acid entry into the mitochondrial matrix for beta-oxidation. - This enzyme controls the transport of fatty acyl-CoA into the mitochondria, which is essential for its subsequent breakdown. *Carnitine acyl transferase I is inhibited by malonyl CoA.* - **Malonyl CoA**, a precursor in fatty acid synthesis, serves as an allosteric inhibitor of **CAT1**. - This mechanism ensures that when the cell is actively synthesizing fatty acids, it simultaneously prevents their breakdown, helping to regulate overall energy metabolism. *Carnitine Acyl transferase I defect causes a decrease in acylcarnitine levels* - A defect in **CAT1** means fatty acids cannot be efficiently transported into the mitochondria to be converted into acylcarnitine for transport. - This leads to an accumulation of **free fatty acids** in the cytoplasm and a **decrease in acylcarnitine levels** in the blood and tissues, which can be used diagnostically.

Q: Which of the following is not a glycerophospholipid?

Sphingomyelin. ***Sphingomyelin*** - Sphingomyelin is a **sphingolipid**, characterized by a **sphingosine backbone** rather than a glycerol backbone. - It contains a **phosphate group** and **choline head group** attached to the sphingosine. *Lecithin* - **Lecithin** is another name for **phosphatidylcholine**, which is a **glycerophospholipid**. - It has a **glycerol backbone** esterified to two fatty acids and a phosphate group linked to choline. *Cardiolipin* - **Cardiolipin** is a **glycerophospholipid** composed of two phosphatidic acid moieties linked by another glycerol molecule. - It is unique for having **four fatty acyl chains** and is primarily found in the **inner mitochondrial membrane**. *Plasmalogens* - **Plasmalogens** are a class of **glycerophospholipids** characterized by an **ether linkage** at the sn-1 position of the glycerol backbone, instead of an ester linkage. - They also contain an **ester-linked fatty acid** at the sn-2 position and a phosphate group with a head group.

Q: Which mineral is required for cholesterol biosynthesis?

Mg. ***Mg*** - **Magnesium (Mg)** is an essential cofactor for multiple enzymes in **cholesterol biosynthesis**, particularly the **ATP-dependent kinases** in the mevalonate pathway. - **Mevalonate kinase** and **phosphomevalonate kinase** require Mg²⁺ as a cofactor for their catalytic activity. - **Squalene synthase**, which catalyzes the formation of squalene from farnesyl pyrophosphate, also requires Mg²⁺. - Deficiency in magnesium can impair these critical steps in **cholesterol synthesis**. *Fe* - **Iron (Fe)** is vital for many enzymatic reactions, particularly in **oxygen transport** (hemoglobin), **electron transport** (cytochromes), and **energy metabolism**. - It does not function as a cofactor in the enzymatic steps of **cholesterol biosynthesis**. *Mn* - **Manganese (Mn)** serves as a cofactor for enzymes involved in **carbohydrate metabolism**, **bone formation**, and **antioxidant defense** (superoxide dismutase). - While important for various metabolic processes, it is not specifically required for **cholesterol synthesis**. *Cu* - **Copper (Cu)** is a component of several enzymes, including **cytochrome c oxidase** and **superoxide dismutase**, involved in electron transport and antioxidant defense. - It does not play a direct role as a cofactor in the key enzymatic steps of **cholesterol synthesis**.

Q: Which of the following is increased in lipoprotein lipase deficiency?

Chylomicrons. ***Chylomicrons*** - **Lipoprotein lipase (LPL)** is essential for hydrolyzing triglycerides within **chylomicrons** and VLDL, allowing fatty acids to be taken up by tissues. - Deficiency in LPL leads to a significant accumulation of **chylomicrons** in the plasma, as their degradation is impaired, resulting in **hypertriglyceridemia**. *VLDL* - While LPL also breaks down **VLDL**, the primary and most dramatic accumulation in LPL deficiency is seen with **chylomicrons** due to their larger triglyceride content and direct dependence on LPL for clearance after meals. - **VLDL** levels might also be elevated, but the hallmark is the very high **chylomicron** levels. *LDL* - **LDL** is formed from the catabolism of VLDL, and its levels are generally not directly increased due to a primary LPL deficiency. - LPL's main role is in triglyceride-rich lipoprotein metabolism, not directly in **LDL** catabolism. *HDL* - **HDL** plays a role in reverse cholesterol transport and is not directly metabolized by lipoprotein lipase. - In fact, in severe hypertriglyceridemia due to LPL deficiency, **HDL** levels may sometimes be low rather than increased.

Q: Aromatase produces estrogen from -

Androgen. ***Androgen*** - **Aromatase** is an enzyme complex that converts **androgens** (specifically androstenedione and testosterone) into **estrogens** (estrone and estradiol, respectively). - This conversion is a key step in **estrogen biosynthesis** and occurs in various tissues, including the ovaries, placenta, brain, and adipose tissue. *Progesterone* - **Progesterone** is a precursor to androgens, but it is not directly converted to estrogen by aromatase. - It plays a primary role in the **menstrual cycle** and **pregnancy**. *Cortisol* - **Cortisol** is a **glucocorticoid hormone** produced in the adrenal cortex and is not a substrate for aromatase. - Its primary functions relate to stress response, metabolism, and immune regulation. *Aldosterone* - **Aldosterone** is a **mineralocorticoid hormone** produced in the adrenal cortex and is not involved in estrogen synthesis. - It primarily regulates **blood pressure** and electrolyte balance.

Q: Which of the following is the rate limiting step in cholesterol synthesis?

HMG CoA reductase. ***HMG CoA reductase*** - **HMG-CoA reductase** catalyzes the conversion of **HMG-CoA** to **mevalonate**, which is the committed and rate-limiting step in cholesterol synthesis. - This enzyme is a major target for **statins**, a class of drugs used to lower cholesterol levels by inhibiting its activity. *Thiokinase* - **Thiokinase** (or fatty acyl-CoA synthetase) is involved in activating fatty acids for metabolism, not directly in cholesterol synthesis. - It catalyzes the formation of **fatty acyl-CoA** from fatty acids and CoA, a step in fatty acid metabolism. *Mevalonate kinase* - **Mevalonate kinase** catalyzes the phosphorylation of mevalonate to **5-phosphomevalonate**. - While essential for cholesterol synthesis, this step occurs after the rate-limiting step and is not the primary regulatory point. *HMG CoA synthase* - **HMG-CoA synthase** catalyzes the condensation of **acetoacetyl-CoA** with **acetyl-CoA** to form **HMG-CoA**. - This step occurs before the reduction of HMG-CoA by HMG-CoA reductase and is not the rate-limiting enzyme in the pathway.

Q: What is the primary defect associated with type II hyperlipidemia?

LDL receptor. ***LDL receptor*** - A defect in the **LDL receptor** leads to type II hyperlipidemia, characterized by elevated **LDL cholesterol** levels in the blood [1]. - This condition results in increased risk for **atherosclerosis** and cardiovascular diseases due to impaired cellular uptake of cholesterol [1,2]. *Apo-E* - Deficiencies of **Apo-E** typically result in type III hyperlipidemia, associated with **remnant lipoprotein clearance** issues rather than type II. - It affects metabolism of **chylomicron remnants** and intermediate density lipoproteins (IDL), not primarily LDL. *None* - This option incorrectly suggests that there is no defect associated with type II hyperlipidemia; in reality, it is primarily linked to **LDL receptor** dysfunction [1]. - The term "none" implies a lack of specific pathology, which is inaccurate in the context of hyperlipidemia types. *Lipoprotein lipase* - Deficiency in **lipoprotein lipase** leads to type I (or V) hyperlipidemia, characterized by increased **triglyceride** levels rather than just LDL. - It primarily impairs the hydrolysis of triglycerides in chylomicrons and VLDL, which differs from the LDL receptor's function [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 157-159. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 156-157.

Q: Oxidation of very long chain fatty acids takes place in ?

Peroxisomes. ***Peroxisomes (Correct)*** - **Very long chain fatty acids (VLCFAs)**, which have more than 20 carbon atoms, undergo initial **beta-oxidation** in peroxisomes. - This process shortens the VLCFAs before they are transported to mitochondria for further oxidation. - Peroxisomes are essential for breaking down these fatty acids that are too long for direct mitochondrial processing. *Cytosol (Incorrect)* - The cytosol is the site for **fatty acid synthesis**, not oxidation. - It also plays a role in the initial steps of **glycerol phosphorylation** in triglyceride synthesis. *Mitochondria (Incorrect)* - **Mitochondria** primarily handle the beta-oxidation of **medium and short-chain fatty acids** (typically less than 20 carbons). - While VLCFAs are eventually oxidized here after peroxisomal shortening, their initial breakdown must occur in peroxisomes. *Ribosomes (Incorrect)* - **Ribosomes** are responsible for **protein synthesis** (translation) based on mRNA templates. - They have no role in fatty acid metabolism.

Question 1

Which of the following statements about beta oxidation of fatty acids is correct?

Accepted Answer

Fatty acid oxidation defects can lead to hypoglycemia.

Answer

Ketone bodies are formed by complete oxidation of fatty acids during starvation.

Answer

Odd chain fatty acid oxidation provides only propionyl CoA.

Answer

Stearic acid on oxidation provides 120 ATPs.

Question 2

Arachidonic acid oxidation involves how many cycles of beta oxidation?

Accepted Answer

9

Answer

20

Answer

8

Answer

10

Question 3

All are true about beta oxidation of fatty acids except which of the following?

Accepted Answer

Carnitine Acyl transferase I is stimulated by malonyl CoA

Answer

Carnitine Acyl transferase I defect causes a decrease in acylcarnitine levels

Answer

Carnitine acyl transferase I is the rate limiting enzyme of fatty acid oxidation

Answer

Carnitine acyl transferase I is inhibited by malonyl CoA

Question 4

Which of the following is not a glycerophospholipid?

Accepted Answer

Sphingomyelin

Answer

Lecithin

Answer

Cardiolipin

Answer

Plasmalogens

Question 5

Which mineral is required for cholesterol biosynthesis?

Accepted Answer

Mg

Answer

Fe

Answer

Mn

Answer

Cu

Question 6

Which of the following is increased in lipoprotein lipase deficiency?

Accepted Answer

Chylomicrons

Answer

VLDL

Answer

LDL

Answer

HDL

Question 7

Aromatase produces estrogen from -

Accepted Answer

Androgen

Answer

Progesterone

Answer

Cortisol

Answer

Aldosterone

Question 8

Which of the following is the rate limiting step in cholesterol synthesis?

Accepted Answer

HMG CoA reductase

Answer

Thiokinase

Answer

Mevalonate kinase

Answer

HMG CoA synthase

Question 9

What is the primary defect associated with type II hyperlipidemia?

Accepted Answer

LDL receptor

Answer

Apo-E

Answer

Lipoprotein lipase

Answer

HMG-CoA reductase

Question 10

Oxidation of very long chain fatty acids takes place in ?

Accepted Answer

Peroxisomes

Answer

Ribosomes

Answer

Cytosol

Answer

Mitochondria

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?